{ "cells": [ { "cell_type": "code", "execution_count": 1, "metadata": {}, "outputs": [], "source": [ "import pandas as pd\n", "from OpenAITools.JRCTTools import fetch_clinical_trials, extract_jrct_links, create_dataframe_from_urls, reorder_columns" ] }, { "cell_type": "code", "execution_count": 2, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "検索ボタンがクリックできないため、JavaScriptでクリックします。\n", "ページネーションが存在しません。全ての結果を取得しました。\n" ] } ], "source": [ "# fetch_clinical_trialsを使って検索結果を取得\n", "results = fetch_clinical_trials(disease_name=\"肉腫\", freeword=\"\",include_not_yet_recruiting=True)" ] }, { "cell_type": "code", "execution_count": 3, "metadata": {}, "outputs": [ { "data": { "text/plain": [ "['初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉腫など）',\n", " '切除不能皮膚血管肉腫',\n", " '軟部肉腫',\n", " '未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫',\n", " '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n", " '後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫',\n", " '標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん',\n", " '皮膚血管肉腫',\n", " '後腹膜脱分化型脂肪肉腫',\n", " '骨軟部肉腫',\n", " '切除可能高悪性度非円形細胞軟部肉腫',\n", " '・肉腫、ユーイング 、・新生物転移',\n", " '高悪性骨肉腫',\n", " '標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍',\n", " '【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・HRD陽性の子宮平滑筋...',\n", " '横紋筋肉腫',\n", " '横紋筋肉腫',\n", " 'ユーイング肉腫ファミリー腫瘍',\n", " '進行骨軟部肉腫',\n", " '悪性骨軟部腫瘍（骨軟部肉腫）',\n", " '頭蓋底脊索腫・軟骨肉腫']" ] }, "execution_count": 3, "metadata": {}, "output_type": "execute_result" } ], "source": [ "[result[2] for result in results]" ] }, { "cell_type": "code", "execution_count": 4, "metadata": {}, "outputs": [ { "name": "stdout", "output_type": "stream", "text": [ "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1060240085\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031240448\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs061240064\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2061240032\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1030240137\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031230482\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033230299\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2021230016\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs041230007\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs032220609\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs031220446\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2071220043\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs041220024\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2033220088\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT2031210264\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051180207\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051180200\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs021180022\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs051180042\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCTs052180038\n", "Waiting for 5 seconds before the next request...\n", "Processing URL: https://jrct.niph.go.jp/latest-detail/jRCT1032180086\n", "Waiting for 5 seconds before the next request...\n" ] } ], "source": [ " # jRCT詳細リンクを作成\n", "jrct_links = extract_jrct_links(results)\n", "\n", " # 詳細リンクからデータフレームを作成\n", "df = create_dataframe_from_urls(jrct_links,delay=5)" ] }, { "cell_type": "code", "execution_count": 6, "metadata": {}, "outputs": [], "source": [ "# 整列後の DataFrame を作成\n", "sorted_df = reorder_columns(df)" ] }, { "cell_type": "code", "execution_count": 7, "metadata": {}, "outputs": [ { "name": "stderr", "output_type": "stream", "text": [ "/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_93066/3932068550.py:1: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " sorted_df['JRCT ID'] = [result[0] for result in results]\n", "/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_93066/3932068550.py:2: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " sorted_df['Title'] = [result[1] for result in results]\n", "/var/folders/xj/t9whz9_x5g309fn84ql50wrm0000gn/T/ipykernel_93066/3932068550.py:3: SettingWithCopyWarning: \n", "A value is trying to be set on a copy of a slice from a DataFrame.\n", "Try using .loc[row_indexer,col_indexer] = value instead\n", "\n", "See the caveats in the documentation: https://pandas.pydata.org/pandas-docs/stable/user_guide/indexing.html#returning-a-view-versus-a-copy\n", " sorted_df['Target'] = [result[2] for result in results]\n" ] } ], "source": [ "sorted_df['JRCT ID'] = [result[0] for result in results]\n", "sorted_df['Title'] = [result[1] for result in results]\n", "sorted_df['Target'] = [result[2] for result in results]" ] }, { "cell_type": "code", "execution_count": 8, "metadata": {}, "outputs": [], "source": [ "new_order = [\"JRCT ID\", \"Title\",'Target'] + [col for col in sorted_df.columns if col not in [\"JRCT ID\", \"Title\",'Target']]" ] }, { "cell_type": "code", "execution_count": 9, "metadata": {}, "outputs": [], "source": [ "sorted_df = sorted_df[new_order]" ] }, { "cell_type": "code", "execution_count": 10, "metadata": {}, "outputs": [ { "data": { "text/html": [ "
\n", "\n", "\n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", " \n", "
JRCT IDTitleTarget研究・治験の目的試験の種類無作為化盲検化対照割付け研究目的...Inclusion CriteriaExclusion CriteriaAge MinimumAge MaximumGenderDiscontinuation CriteriaKeywordIntervention(s)PhaseTarget
0jRCT1060240085小児およびAYA肝腫瘍における術前３Ｄシミュレーションとそれに基づく術式立案システムの実行可...初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉...本研究の目的は、小児・AYA肝腫瘍を対象として現在おこなっている中央画像診断、中央病理診断に...観察研究単一群非盲検非対照単群比較治療...1. Diagnosed or suspected to have a non-treate...If the research director or co-researchers det...No limit40age old notNonehepatoblastoma, HCN-NOS, hepatocellular carcin...NaN初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉...
1jRCT2031240448切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の第II相医師主導治験切除不能皮膚血管肉腫切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の有効性を検証し、有効性と...NaN単一群非盲検非対照単群比較治療...1)\\tHistologically diagnosed with cutaneous an...1)\\tPatients previously treated with anti-PD-1...18age old over85age old underBothNonecutaneous angiosarcoma, angiosarcomaEach course is set at 21 days. Pembrolizumab 2...NaN切除不能皮膚血管肉腫
2jRCTs061240064進行期悪性軟部腫瘍に対するドキソルビシン及びトラベクテジン併用療法の有効性に関する非対照研究軟部肉腫進行期軟部肉腫患者に対するドキソルビシンとトラベクテジン併用療法の有効性を無増悪生存期間，疾...介入研究単一群非盲検ヒストリカルコントロール単群比較治療...1. Patients with pathologically diagnosed mali...1. Patients who have received a cumulative dos...18age old exceedNo limitBothNoneSoft tissue sarcomaDoxorubicin (60 mg/m2) for 15 minutes, Trabect...NaN軟部肉腫
3jRCT206124003218歳以上の未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通...未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫Grade 1及びGrade 2の患者を対象に盲検化独立中央判定者（BICR）による腫瘍評価...NaN無作為化比較二重盲検プラセボ対照並行群間比較治療...Have a histopathological diagnosis (fresh or b...Are unable to swallow oral medication.\\n\\r\\nPr...18age old overNo limitBothNoneChondrosarcomaDrug: Ivosidenib 500mg or Placebo\\n\\r\\nProvide...NaN未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫
4jRCT1030240137EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細...標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がんCARTiEr試験において、AP8901が投与された被検者におけるヒト体内での動態ならびに作...観察研究単一群非盲検非対照単群比較治療...1.Patients enrolled in CARTiEr study\\n\\r\\n2.Wr...1.Written consent has not been obtained from t...18age old overNo limitBothNoneNaN標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん
5jRCTs031230482JCOG2214INT: 高リスク後腹膜肉腫に対する術前補助化学療法の意義に関するランダム化...後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫切除可能な後腹膜発生高リスク脱分化型脂肪肉腫および平滑筋肉腫を対象に、標準治療である根治的手...介入研究無作為化比較非盲検実薬（治療）対照並行群間比較治療...* Histologically proven primary high risk leio...* Sarcoma originating from bone structure, abd...18age old overNo limitBothNonePatients in the standard arm (surgery alone) w...NaN後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫
6jRCT2033230299EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細...標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん転移・再発に対して標準治療がない又は不応若しくは不耐の EPHB4 受容体を発現するユーイン...NaN単一群非盲検非対照単群比較治療...1.Patients who have voluntarily provided writt...1.Patients with other malignancies or history ...18age old overNo limitBothNoneAdministration of CAR-T cells produced from er...NaN標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん
7jRCT2021230016皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験皮膚血管肉腫皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお...NaN単一群非盲検非対照単群比較治療...(1) Patients who are 18 years old over (at the...(1) Patients with concomitant or pre-existing ...18age old overNo limitBothNone(TM5614)\\n\\r\\nTM5614 should be taken orally af...NaN皮膚血管肉腫
8jRCTs041230007後腹膜脱分化型脂肪肉腫に対する術前AI（ドキソルビシン・イホスファミド）療法の単群第Ⅱ相試験後腹膜脱分化型脂肪肉腫肉眼的根治切除をし得た後腹膜脱分化型脂肪肉腫患者の術前ドキソルビシン・イホスファミド療法の有...介入研究単一群非盲検非対照単群比較治療...The patients diagnosed with de-differentiated ...The patients have a severe allergy and drug hy...18age old overNo limitBothNoneretroperitoneal de-differentiated liposarcomaDoxorubicin (20mg/m2/day), IV, given on day1-3...NaN後腹膜脱分化型脂肪肉腫
9jRCTs032220609骨軟部肉腫に対する線量平均LET最適化マルチイオン重粒子線治療のFeasibility臨床研究骨軟部肉腫骨軟部肉腫に対して既存の重粒子線治療法の生物線量を維持しつつ、腫瘍内の線量平均LET値の最適...介入研究単一群非盲検非対照単群比較治療...1. Histologically diagnosed high-grade bone an...1.\\tPatients with serious complications.\\n\\r\\n...No limitNo limitBothNonesarcomaMulti-ion radiotherapyNaN骨軟部肉腫
10jRCTs031220446JCOG2102: 切除可能高悪性度非円形細胞軟部肉腫に対する術前術後補助化学療法と術後補助...切除可能高悪性度非円形細胞軟部肉腫切除可能なStage IIIA/B（T2-4N0M0）の非円形細胞軟部肉腫を対象に、標準治療...介入研究無作為化比較非盲検実薬（治療）対照並行群間比較治療...(1) Grade 2 or 3 (FNCLCC histological grading ...(1) Synchronous or metachronous (within 5 year...16age old over70age old underBothNoneArm A: Three courses of preoperative chemother...NaN切除可能高悪性度非円形細胞軟部肉腫
11jRCT2071220043再発又は難治性ユーイング肉腫を有する患者を対象に、イリノテカン及びテモゾロミドと併用したとき...・肉腫、ユーイング 、・新生物転移CAMPFIRE：ユーイング肉腫患者を対象としたアベマシクリブ（LY2835219)の研究NaN無作為化比較非盲検実薬（治療）対照並行群間比較治療...-Diagnosis of Ewing's sarcoma or Ewing's sarco...-Participants with severe and/or uncontrolled ...1age old over39age old underBothNone-Drug: Abemaciclib\\n\\r\\n Orally\\n\\r\\n Ot...NaN・肉腫、ユーイング 、・新生物転移
12jRCTs041220024高悪性骨肉腫を対象としたメトトレキサート・アドリアマイシン・シスプラチン（MAP）療法にがん...高悪性骨肉腫臨床病期ⅡA、ⅡB、Ⅲ期、Ⅳ期又は術後再発の高悪性骨肉腫患者に対してファスジル＋MAP療法（...介入研究単一群非盲検非対照単群比較治療...1.\\tStage2A, 2B, 3,4, or recurrent high grade ...1.\\tLatest adequate organ function as proved b...14age old over65age old notBothNonefasudil hydrochloride hydrate as an IV infusionNaN高悪性骨肉腫
13jRCT2033220088HER2特異的キメラ抗原受容体（CAR）遺伝子改変T細胞療法の安全性に関する臨床第Ⅰ相試験標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍標準治療により不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍患者...NaN単一群非盲検非対照単群比較治療...SC1 (before apheresis)\\n\\r\\n1. Patients diagno...SC1 (pre-apheresis), SC2 (pre-treatment initia...5age old over65age old notBothNoneAdministration of CAR-T cells produced from er...NaN標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍
14jRCT2031210264HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する単群...【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H...HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する。NaN単一群非盲検非対照単群比較治療...Patients who meet all of the following criteri...Subject will be excluded from the trial if the...20age old overNo limitFemaleNonegynecology, malignancy, rare, gynecologic rare...A 200 mg dose of niraparib is orally administe...NaN【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H...
15jRCTs051180207横紋筋肉腫中間リスク群患者に対するVAC2.2（ビンクリスチン、アクチノマイシンD、シクロホ...横紋筋肉腫Stage 2、3、Group IIIに分類される胎児型横紋筋肉腫、Group I, II、...介入研究単一群非盲検無治療対照/標準治療対照単群比較治療...1) Histologically confirmed newly diagnosed rh...1) patients with synchronous or metachronous c...1age old over29age old underBothNoneRhabdomyosarcomachemotherapy 43 weeks \\n\\r\\nVAC2.2 therapy 9 c...NaN横紋筋肉腫
16jRCTs051180200横紋筋肉腫低リスクB群患者に対するVAC1.2（ビンクリスチン、アクチノマイシンD、シクロホ...横紋筋肉腫Stage 1、 Group III（眼窩Group III N0、NXを除く）、または、S...介入研究単一群非盲検非対照単群比較治療...1) Histologically confirmed newly diagnosed em...1) patients with primary tumor of CNS origin, ...No limit29age old underBothNonerhabdomyosarcomachemotherapy 43 weeks \\n\\r\\nVAC1.2 therapy 9 c...NaN横紋筋肉腫
17jRCTs021180022限局性ユーイング肉腫ファミリー腫瘍に対するG-CSF併用治療期間短縮VDC-IE療法を用いた...ユーイング肉腫ファミリー腫瘍新規に診断された限局性ユーイング肉腫ファミリー腫瘍（ESFT）に対して、VDC-IE療法を顆...介入研究単一群非盲検非対照単群比較治療...1. Histologically confirmed newly diagnosed ES...1. Patients with synchronous or metachronous c...No limit50age 0month old notBothNoneEwing sarcomaChemotherapy\\n\\r\\nStandard therapy for localiz...NaNユーイング肉腫ファミリー腫瘍
18jRCTs051180042進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法の第Ⅱ相臨床試験進行骨軟部肉腫本試験は、再発または遠隔転移を有する進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法...介入研究単一群非盲検非対照単群比較治療...1)Patients are histopathologically diagnosed a...1)Active double cancers within 5 years(cured i...10age 0month 0week old over70age 11month 4week old underBothNoneGemcitabine (900 mg/m2) intravenously(IV) on D...NaN進行骨軟部肉腫
19jRCTs052180038炭酸ガス経皮吸収による悪性骨軟部腫瘍に対する安全性および抗腫瘍効果に関する探索的臨床研究悪性骨軟部腫瘍（骨軟部肉腫）悪性骨軟部腫瘍に対する炭酸ガス経皮吸収の安全性と有用性を評価すること介入研究単一群非盲検非対照単群比較治療...(1) Patients who have been histologically diag...(1) Skin ulcer or pathological fracture in the...16age old overNo limitBothNonesarcomaTranscutaneous carbon dioxide (CO2) applicatio...NaN悪性骨軟部腫瘍（骨軟部肉腫）
20jRCT1032180086頭蓋底脊索腫・軟骨肉腫術後に対する陽子線治療の有効性・安全性を評価する第II相試験頭蓋底脊索腫・軟骨肉腫頭蓋底脊索腫術後に対する陽子線治療の有効性・安全性判定介入研究単一群非盲検非対照単群比較治療...1, Pathological diagnosis is chordoma or chond...1, Multiple primary cancers\\n\\r\\n2, Invasion f...15age old overNo limitBothNoneproton radiation therapy, proton beam therapy,...Proton Radiation TherapyNaN頭蓋底脊索腫・軟骨肉腫
\n", "

21 rows × 36 columns

\n", "
" ], "text/plain": [ " JRCT ID Title \\\n", "0 jRCT1060240085 小児およびAYA肝腫瘍における術前３Ｄシミュレーションとそれに基づく術式立案システムの実行可... \n", "1 jRCT2031240448 切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の第II相医師主導治験 \n", "2 jRCTs061240064 進行期悪性軟部腫瘍に対するドキソルビシン及びトラベクテジン併用療法の有効性に関する非対照研究 \n", "3 jRCT2061240032 18歳以上の未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通... \n", "4 jRCT1030240137 EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細... \n", "5 jRCTs031230482 JCOG2214INT: 高リスク後腹膜肉腫に対する術前補助化学療法の意義に関するランダム化... \n", "6 jRCT2033230299 EPHB4受容体発現のユーイング肉腫又は固形がんを対象とした非ウイルス遺伝子改変CAR-T細... \n", "7 jRCT2021230016 皮膚血管肉腫に対するパクリタキセルとTM5614併用の安全性・有効性を検討する第Ⅱ相医師主導治験 \n", "8 jRCTs041230007 後腹膜脱分化型脂肪肉腫に対する術前AI（ドキソルビシン・イホスファミド）療法の単群第Ⅱ相試験 \n", "9 jRCTs032220609 骨軟部肉腫に対する線量平均LET最適化マルチイオン重粒子線治療のFeasibility臨床研究 \n", "10 jRCTs031220446 JCOG2102: 切除可能高悪性度非円形細胞軟部肉腫に対する術前術後補助化学療法と術後補助... \n", "11 jRCT2071220043 再発又は難治性ユーイング肉腫を有する患者を対象に、イリノテカン及びテモゾロミドと併用したとき... \n", "12 jRCTs041220024 高悪性骨肉腫を対象としたメトトレキサート・アドリアマイシン・シスプラチン（MAP）療法にがん... \n", "13 jRCT2033220088 HER2特異的キメラ抗原受容体（CAR）遺伝子改変T細胞療法の安全性に関する臨床第Ⅰ相試験 \n", "14 jRCT2031210264 HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する単群... \n", "15 jRCTs051180207 横紋筋肉腫中間リスク群患者に対するVAC2.2（ビンクリスチン、アクチノマイシンD、シクロホ... \n", "16 jRCTs051180200 横紋筋肉腫低リスクB群患者に対するVAC1.2（ビンクリスチン、アクチノマイシンD、シクロホ... \n", "17 jRCTs021180022 限局性ユーイング肉腫ファミリー腫瘍に対するG-CSF併用治療期間短縮VDC-IE療法を用いた... \n", "18 jRCTs051180042 進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法の第Ⅱ相臨床試験 \n", "19 jRCTs052180038 炭酸ガス経皮吸収による悪性骨軟部腫瘍に対する安全性および抗腫瘍効果に関する探索的臨床研究 \n", "20 jRCT1032180086 頭蓋底脊索腫・軟骨肉腫術後に対する陽子線治療の有効性・安全性を評価する第II相試験 \n", "\n", " Target \\\n", "0 初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉... \n", "1 切除不能皮膚血管肉腫 \n", "2 軟部肉腫 \n", "3 未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫 \n", "4 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n", "5 後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫 \n", "6 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n", "7 皮膚血管肉腫 \n", "8 後腹膜脱分化型脂肪肉腫 \n", "9 骨軟部肉腫 \n", "10 切除可能高悪性度非円形細胞軟部肉腫 \n", "11 ・肉腫、ユーイング 、・新生物転移 \n", "12 高悪性骨肉腫 \n", "13 標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍 \n", "14 【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H... \n", "15 横紋筋肉腫 \n", "16 横紋筋肉腫 \n", "17 ユーイング肉腫ファミリー腫瘍 \n", "18 進行骨軟部肉腫 \n", "19 悪性骨軟部腫瘍（骨軟部肉腫） \n", "20 頭蓋底脊索腫・軟骨肉腫 \n", "\n", " 研究・治験の目的 試験の種類 無作為化 盲検化 \\\n", "0 本研究の目的は、小児・AYA肝腫瘍を対象として現在おこなっている中央画像診断、中央病理診断に... 観察研究 単一群 非盲検 \n", "1 切除不能皮膚血管肉腫に対するペムブロリズマブ＋レンバチニブ併用療法の有効性を検証し、有効性と... NaN 単一群 非盲検 \n", "2 進行期軟部肉腫患者に対するドキソルビシンとトラベクテジン併用療法の有効性を無増悪生存期間，疾... 介入研究 単一群 非盲検 \n", "3 Grade 1及びGrade 2の患者を対象に盲検化独立中央判定者（BICR）による腫瘍評価... NaN 無作為化比較 二重盲検 \n", "4 CARTiEr試験において、AP8901が投与された被検者におけるヒト体内での動態ならびに作... 観察研究 単一群 非盲検 \n", "5 切除可能な後腹膜発生高リスク脱分化型脂肪肉腫および平滑筋肉腫を対象に、標準治療である根治的手... 介入研究 無作為化比較 非盲検 \n", "6 転移・再発に対して標準治療がない又は不応若しくは不耐の EPHB4 受容体を発現するユーイン... NaN 単一群 非盲検 \n", "7 皮膚血管肉腫のパクリタキセル単剤療法無効症例を対象にTM5614とパクリタキセルの併用時にお... NaN 単一群 非盲検 \n", "8 肉眼的根治切除をし得た後腹膜脱分化型脂肪肉腫患者の術前ドキソルビシン・イホスファミド療法の有... 介入研究 単一群 非盲検 \n", "9 骨軟部肉腫に対して既存の重粒子線治療法の生物線量を維持しつつ、腫瘍内の線量平均LET値の最適... 介入研究 単一群 非盲検 \n", "10 切除可能なStage IIIA/B（T2-4N0M0）の非円形細胞軟部肉腫を対象に、標準治療... 介入研究 無作為化比較 非盲検 \n", "11 CAMPFIRE：ユーイング肉腫患者を対象としたアベマシクリブ（LY2835219)の研究 NaN 無作為化比較 非盲検 \n", "12 臨床病期ⅡA、ⅡB、Ⅲ期、Ⅳ期又は術後再発の高悪性骨肉腫患者に対してファスジル＋MAP療法（... 介入研究 単一群 非盲検 \n", "13 標準治療により不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍患者... NaN 単一群 非盲検 \n", "14 HRD陽性再発・難治性婦人科希少がんに対するNiraparibの安全性・有効性を評価する。 NaN 単一群 非盲検 \n", "15 Stage 2、3、Group IIIに分類される胎児型横紋筋肉腫、Group I, II、... 介入研究 単一群 非盲検 \n", "16 Stage 1、 Group III（眼窩Group III N0、NXを除く）、または、S... 介入研究 単一群 非盲検 \n", "17 新規に診断された限局性ユーイング肉腫ファミリー腫瘍（ESFT）に対して、VDC-IE療法を顆... 介入研究 単一群 非盲検 \n", "18 本試験は、再発または遠隔転移を有する進行骨軟部肉腫に対するゲムシタビン/ドセタキセル併用療法... 介入研究 単一群 非盲検 \n", "19 悪性骨軟部腫瘍に対する炭酸ガス経皮吸収の安全性と有用性を評価すること 介入研究 単一群 非盲検 \n", "20 頭蓋底脊索腫術後に対する陽子線治療の有効性・安全性判定 介入研究 単一群 非盲検 \n", "\n", " 対照 割付け 研究目的 ... \\\n", "0 非対照 単群比較 治療 ... \n", "1 非対照 単群比較 治療 ... \n", "2 ヒストリカルコントロール 単群比較 治療 ... \n", "3 プラセボ対照 並行群間比較 治療 ... \n", "4 非対照 単群比較 治療 ... \n", "5 実薬（治療）対照 並行群間比較 治療 ... \n", "6 非対照 単群比較 治療 ... \n", "7 非対照 単群比較 治療 ... \n", "8 非対照 単群比較 治療 ... \n", "9 非対照 単群比較 治療 ... \n", "10 実薬（治療）対照 並行群間比較 治療 ... \n", "11 実薬（治療）対照 並行群間比較 治療 ... \n", "12 非対照 単群比較 治療 ... \n", "13 非対照 単群比較 治療 ... \n", "14 非対照 単群比較 治療 ... \n", "15 無治療対照/標準治療対照 単群比較 治療 ... \n", "16 非対照 単群比較 治療 ... \n", "17 非対照 単群比較 治療 ... \n", "18 非対照 単群比較 治療 ... \n", "19 非対照 単群比較 治療 ... \n", "20 非対照 単群比較 治療 ... \n", "\n", " Inclusion Criteria \\\n", "0 1. Diagnosed or suspected to have a non-treate... \n", "1 1)\\tHistologically diagnosed with cutaneous an... \n", "2 1. Patients with pathologically diagnosed mali... \n", "3 Have a histopathological diagnosis (fresh or b... \n", "4 1.Patients enrolled in CARTiEr study\\n\\r\\n2.Wr... \n", "5 * Histologically proven primary high risk leio... \n", "6 1.Patients who have voluntarily provided writt... \n", "7 (1) Patients who are 18 years old over (at the... \n", "8 The patients diagnosed with de-differentiated ... \n", "9 1. Histologically diagnosed high-grade bone an... \n", "10 (1) Grade 2 or 3 (FNCLCC histological grading ... \n", "11 -Diagnosis of Ewing's sarcoma or Ewing's sarco... \n", "12 1.\\tStage2A, 2B, 3,4, or recurrent high grade ... \n", "13 SC1 (before apheresis)\\n\\r\\n1. Patients diagno... \n", "14 Patients who meet all of the following criteri... \n", "15 1) Histologically confirmed newly diagnosed rh... \n", "16 1) Histologically confirmed newly diagnosed em... \n", "17 1. Histologically confirmed newly diagnosed ES... \n", "18 1)Patients are histopathologically diagnosed a... \n", "19 (1) Patients who have been histologically diag... \n", "20 1, Pathological diagnosis is chordoma or chond... \n", "\n", " Exclusion Criteria \\\n", "0 If the research director or co-researchers det... \n", "1 1)\\tPatients previously treated with anti-PD-1... \n", "2 1. Patients who have received a cumulative dos... \n", "3 Are unable to swallow oral medication.\\n\\r\\nPr... \n", "4 1.Written consent has not been obtained from t... \n", "5 * Sarcoma originating from bone structure, abd... \n", "6 1.Patients with other malignancies or history ... \n", "7 (1) Patients with concomitant or pre-existing ... \n", "8 The patients have a severe allergy and drug hy... \n", "9 1.\\tPatients with serious complications.\\n\\r\\n... \n", "10 (1) Synchronous or metachronous (within 5 year... \n", "11 -Participants with severe and/or uncontrolled ... \n", "12 1.\\tLatest adequate organ function as proved b... \n", "13 SC1 (pre-apheresis), SC2 (pre-treatment initia... \n", "14 Subject will be excluded from the trial if the... \n", "15 1) patients with synchronous or metachronous c... \n", "16 1) patients with primary tumor of CNS origin, ... \n", "17 1. Patients with synchronous or metachronous c... \n", "18 1)Active double cancers within 5 years(cured i... \n", "19 (1) Skin ulcer or pathological fracture in the... \n", "20 1, Multiple primary cancers\\n\\r\\n2, Invasion f... \n", "\n", " Age Minimum Age Maximum Gender \\\n", "0 No limit 40age old not \n", "1 18age old over 85age old under Both \n", "2 18age old exceed No limit Both \n", "3 18age old over No limit Both \n", "4 18age old over No limit Both \n", "5 18age old over No limit Both \n", "6 18age old over No limit Both \n", "7 18age old over No limit Both \n", "8 18age old over No limit Both \n", "9 No limit No limit Both \n", "10 16age old over 70age old under Both \n", "11 1age old over 39age old under Both \n", "12 14age old over 65age old not Both \n", "13 5age old over 65age old not Both \n", "14 20age old over No limit Female \n", "15 1age old over 29age old under Both \n", "16 No limit 29age old under Both \n", "17 No limit 50age 0month old not Both \n", "18 10age 0month 0week old over 70age 11month 4week old under Both \n", "19 16age old over No limit Both \n", "20 15age old over No limit Both \n", "\n", " Discontinuation Criteria \\\n", "0 None \n", "1 None \n", "2 None \n", "3 None \n", "4 None \n", "5 None \n", "6 None \n", "7 None \n", "8 None \n", "9 None \n", "10 None \n", "11 None \n", "12 None \n", "13 None \n", "14 None \n", "15 None \n", "16 None \n", "17 None \n", "18 None \n", "19 None \n", "20 None \n", "\n", " Keyword \\\n", "0 hepatoblastoma, HCN-NOS, hepatocellular carcin... \n", "1 cutaneous angiosarcoma, angiosarcoma \n", "2 Soft tissue sarcoma \n", "3 Chondrosarcoma \n", "4 \n", "5 \n", "6 \n", "7 \n", "8 retroperitoneal de-differentiated liposarcoma \n", "9 sarcoma \n", "10 \n", "11 \n", "12 \n", "13 \n", "14 gynecology, malignancy, rare, gynecologic rare... \n", "15 Rhabdomyosarcoma \n", "16 rhabdomyosarcoma \n", "17 Ewing sarcoma \n", "18 \n", "19 sarcoma \n", "20 proton radiation therapy, proton beam therapy,... \n", "\n", " Intervention(s) Phase \\\n", "0 NaN \n", "1 Each course is set at 21 days. Pembrolizumab 2... NaN \n", "2 Doxorubicin (60 mg/m2) for 15 minutes, Trabect... NaN \n", "3 Drug: Ivosidenib 500mg or Placebo\\n\\r\\nProvide... NaN \n", "4 NaN \n", "5 Patients in the standard arm (surgery alone) w... NaN \n", "6 Administration of CAR-T cells produced from er... NaN \n", "7 (TM5614)\\n\\r\\nTM5614 should be taken orally af... NaN \n", "8 Doxorubicin (20mg/m2/day), IV, given on day1-3... NaN \n", "9 Multi-ion radiotherapy NaN \n", "10 Arm A: Three courses of preoperative chemother... NaN \n", "11 -Drug: Abemaciclib\\n\\r\\n Orally\\n\\r\\n Ot... NaN \n", "12 fasudil hydrochloride hydrate as an IV infusion NaN \n", "13 Administration of CAR-T cells produced from er... NaN \n", "14 A 200 mg dose of niraparib is orally administe... NaN \n", "15 chemotherapy 43 weeks \\n\\r\\nVAC2.2 therapy 9 c... NaN \n", "16 chemotherapy 43 weeks \\n\\r\\nVAC1.2 therapy 9 c... NaN \n", "17 Chemotherapy\\n\\r\\nStandard therapy for localiz... NaN \n", "18 Gemcitabine (900 mg/m2) intravenously(IV) on D... NaN \n", "19 Transcutaneous carbon dioxide (CO2) applicatio... NaN \n", "20 Proton Radiation Therapy NaN \n", "\n", " Target \n", "0 初発の小児・AYA世代の肝悪性腫瘍（肝芽腫、HCN-NOS、肝細胞癌、肝内胆管癌、肝未分化肉... \n", "1 切除不能皮膚血管肉腫 \n", "2 軟部肉腫 \n", "3 未治療又は1レジメンの全身治療歴を有するIDH1変異陽性の局所進行又は転移性の通常型軟骨肉腫 \n", "4 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n", "5 後腹膜原発性高リスク脱分化型脂肪肉腫または平滑筋肉腫 \n", "6 標準治療がない又は不応若しくは不耐の進行再発と診断されたユーイング肉腫又は固形がん \n", "7 皮膚血管肉腫 \n", "8 後腹膜脱分化型脂肪肉腫 \n", "9 骨軟部肉腫 \n", "10 切除可能高悪性度非円形細胞軟部肉腫 \n", "11 ・肉腫、ユーイング 、・新生物転移 \n", "12 高悪性骨肉腫 \n", "13 標準治療不応・不耐もしくは再発又は進行HER2陽性骨・軟部肉腫および婦人科悪性腫瘍 \n", "14 【コホートA】BRCA変異陽性の子宮平滑筋肉腫：募集中\\n【コホートB】BRCA変異陰性・H... \n", "15 横紋筋肉腫 \n", "16 横紋筋肉腫 \n", "17 ユーイング肉腫ファミリー腫瘍 \n", "18 進行骨軟部肉腫 \n", "19 悪性骨軟部腫瘍（骨軟部肉腫） \n", "20 頭蓋底脊索腫・軟骨肉腫 \n", "\n", "[21 rows x 36 columns]" ] }, "execution_count": 10, "metadata": {}, "output_type": "execute_result" } ], "source": [ "sorted_df" ] }, { "cell_type": "code", "execution_count": 11, "metadata": {}, "outputs": [], "source": [ "sorted_df.to_csv('../JRCT20241129sarcoma.csv')" ] }, { "cell_type": "code", "execution_count": null, "metadata": {}, "outputs": [], "source": [] } ], "metadata": { "kernelspec": { "display_name": "gradio", "language": "python", "name": "python3" }, "language_info": { "codemirror_mode": { "name": "ipython", "version": 3 }, "file_extension": ".py", "mimetype": "text/x-python", "name": "python", "nbconvert_exporter": "python", "pygments_lexer": "ipython3", "version": "3.12.3" } }, "nbformat": 4, "nbformat_minor": 2 }